<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581333</url>
  </required_header>
  <id_info>
    <org_study_id>2011-005152-34</org_study_id>
    <nct_id>NCT01581333</nct_id>
  </id_info>
  <brief_title>Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia</brief_title>
  <acronym>HOWLONG</acronym>
  <official_title>Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial intended to reduce the antibiotic therapy duration in &quot;in-hospital&quot; patients
      with haematological diseases who develop fever and low white blood cell count (neutropenia).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal duration of the empirical antimicrobial therapy (AT) in hematological patients
      with febrile neutropenia (FN) is unknown. The Infectious Diseases Society of America (IDSA)
      recommends maintaining AT at least until the neutropenia is recovered, because literally
      &quot;years of experience have proven this approach to be safe and effective&quot;. This recommendation
      is likely to cause unnecessarily prolonged treatments, and is against the urgent need of
      optimizing the antimicrobial therapy proposed by IDSA. The main objective of this study is to
      establish whether an individualized clinical protocol is better than the standard criteria
      (recovery of neutropenia as the criterion to suspend the empirical AT in hematological
      patients with FN).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days on which patient is free of antimicrobial treatment</measure>
    <time_frame>28 days following the initiation of empiric antibiotic treatment.</time_frame>
    <description>Protocol visits: Screening visit, Randomization visit, at 72h. of apyrexy (visit 1), at clinical recovery (visit 2), at recovery of neutropenia (visit 3), at relapsing fever (visit 4) and at 28 days (final visit).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Crude mortality</measure>
    <time_frame>28 days following the initiation of empiric antibiotic treatment.</time_frame>
    <description>Number of died patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days of fever</measure>
    <time_frame>28 days following the initiation of empiric antibiotic treatment</time_frame>
    <description>Number of days of fever</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empirical antimicrobial treatment discontinuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard empirical antimicrobial treatment discontinuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empirical antimicrobial treatment discontinuation</intervention_name>
    <description>Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Clinical rules for finalization of antimicrobial therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard empirical antimicrobial treatment discontinuation</intervention_name>
    <description>The empirical antimicrobial treatment discontinuation will occur when the patient is:
The neutrophil count is above 500 million per mm3.</description>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Laboratory rules for finalization of antimicrobial therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (equal or older than 18 years) of both sexes admitted in the Department
             of Clinical Hematology who develop a febrile neutropenia. Including fever with unknown
             source and fever secondary to infection focus of clinical diagnosis without laboratory
             confirmation.

          -  Informed consent signed.

        Exclusion Criteria:

          -  Fever with etiologic diagnosis.

          -  Patients with epilepsy.

          -  Pregnant or lactating women.

          -  Patients with HIV infection.

          -  Patients with severe renal failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José M Cisneros Herreros, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Virgen del Rocío University Hospital/ Biomedicine Institute of Seville (IBIS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virgen del Rocío University Hospital</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>febrile neutropenia</keyword>
  <keyword>antimicrobial treatment</keyword>
  <keyword>procalcitonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Infective Agents</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

